Research Progress in Niacinamide in the Prevention and Treatment of Mouth and Systemic Diseases

LEI Zi-xue, LIN Yong-wang, LI Yu-qing, ZHOU Xue-dong

Abstract

Nicotinamide (NAM) is the amide form of niacin and one of the precursors of nicotinamide adenine dinucleotide (NAD+). NAM can be used as a dietary supplement or clinical therapeutic drug to replenish NAD+ levels in the human body and participate in key bodily functions such as cellular metabolism and DNA repair. NAM has the advantage of low cost, wide availability, and sound biosafety. It also has multiple biological functions, including antibacterial effect, anti-inflammatory effect, and modulation of cellular immunity, producing significant ameliorative effects on skin and neurodegenerative diseases. However, most studies on NAM are still at the laboratory stage. Herein we reviewed the role and mechanism of NAM in the prevention and treatment of oral and systemic diseases, explored its potential as clinical therapeutic medication, provided some basis and references for the clinical application of nicotinamide in the prevention and treatment of various diseases, and discussed its prospects for future research and application.

 

Keywords: Nicotinamide, Skin diseases, Neurodegenerative diseases, Hyperphosphatemia, Mouth diseases

 

Full Text:

PDF


References


LI C， WU L E. Risks and rewards of targeting NAD+ homeostasis in the brain. Mech Ageing Dev，2021，198: 111545. doi: 10.1016/j.mad.2021. 111545.

RAJMAN L， CHWALEK K， SINCLAIR D A. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab，2018，27(3): 529–547. doi: 10.1016/j.cmet.2018.02.011.

ELVEHJEM C A， MADDEN R J， STRONG F M， et al. The isolation and identification of the anti-black tongue factor. Nutr Rev，1974，32(2): 48–50. doi: 10.1111/j.1753-4887.1974.tb06263.x.

COVARRUBIAS A J， PERRONE R， GROZIO A， et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol，2021，22(2): 119–141. doi: 10.1038/s41580-020-00313-x.

GALE E A， BINGLEY P J， EMMETT C L， et al. European nicotinamide diabetes intervention trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet，2004，363(9413): 925–931. doi: 10.1016/S0140-6736(04)15786-3.

El-KADY R R， ALI A K， El WAKEEL L M， et al. Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial. Ther Adv Chronic Dis，2022，13: 20406223221077960. doi: 10.1177/20406223221077958.

KNIP M， DOUEK I F， MOORE W P T， et al. Safety of high-dose nicotinamide: A review. Diabetologia，2000，43(11): 1337–1345. doi: 10. 1007/s001250051536.

RYMARCHYK S， KANG W， CEN Y. Substrate-dependent sensitivity of SIRT1 to nicotinamide inhibition. Biomolecules，2021，11(2): 312. doi: 10. 3390/biom11020312.

LIN Y， GONG T， MA Q， et al. Nicotinamide could reduce growth and cariogenic virulence of Streptococcus mutans. J Oral Microbiol，2022， 14(1): 2056291. doi: 10.1080/20002297.2022.2056291.

VILA T， SULTAN A S， MONTELONGO-JAUREGUI D， et al. Oral candidiasis: a disease of opportunity. J Fungi (Basel)，2020，6(1): E15. doi: 10.3390/jof6010015.

XIAO J， HUANG X， ALKHERS N， et al. Candida albicans and early childhood caries: a systematic review and meta-analysis. Caries Res， 2018，52(1/2): 102–112. doi: 10.1159/000481833.

DU Q， REN B， HE J， et al. Candida albicans promotes tooth decay by inducing oral microbial dysbiosis. ISME J，2021，15(3): 894–908. doi: 10. 1038/s41396-020-00823-8.

XING X， LIAO Z， TAN F， et al. Effect of nicotinamide against Candida albicans. Front Microbiol，2019，10: 595. doi: 10.3389/fmicb.2019.00595.

YAN Y， LIAO Z， SHEN J， et al. Nicotinamide potentiates amphotericin B activity against Candida albicans. Virulence，2022，13(1): 1533–1542. doi: 10.1080/21505594.2022.2119656.

Von KÖCKRITZ A， STÄNDER S， ZEIDLER C， et al. Successful monotherapy of pemphigus vegetans with minocycline and nicotinamide. J Eur Acad Dermatol Venereol，2017，31(1): 85–88. doi: 10.1111/jdv. 13779.

SHIH Y H， LIU D， CHEN Y C， et al. Activation of deoxyribonuclease ⅰ by nicotinamide as a new strategy to attenuate tetracycline-resistant biofilms of Cutibacterium acnes. Pharmaceutics，2021，13(6): 819. doi: 10. 3390/pharmaceutics13060819.

GRANGE P A， RAINGEAUD J， CALVEZ V， et al. Nicotinamide inhibits Propionibacterium acnes-induced IL-8 production in keratinocytes through the NF-kappaB and MAPK pathways. J Dermatol Sci，2009，56(2): 106–112. doi: 10.1016/j.jdermsci.2009.08.001.

NASR M， KARANDIKAR H， ABDEL-AZIZ R T A， et al. Novel nicotinamide skin-adhesive hot melt extrudates for treatment of acne. Expert Opin Drug Deliv，2018，15(12): 1165–1173. doi: 10.1080/17425247. 2018.1546287.

ABD-ALLAH H， ABDEL-AZIZ R T A， NASR M. Chitosan nanoparticles making their way to clinical practice: a feasibility study on their topical use for acne treatment. Int J Biol Macromol，2020，156: 262–270. doi: 10. 1016/j.ijbiomac.2020.04.040.

PHILIPS N， CHALENSOUK-KHAOSAAT J， GONZALEZ S. Simulation of the elastin and fibrillin in non-irradiated or UVA radiated fibroblasts, and direct inhibition of elastase or matrix metalloptoteinases activity by nicotinamide or its derivatives. J Cosmet Sci，2018，69(1): 47–56.

TAN C Y R， TAN C L， CHIN T， et al. Nicotinamide prevents UVB- and oxidative stress-induced photoaging in human primary keratinocytes. J Invest Dermatol，2022，142(6): 1670–1681.e12. doi: 10.1016/j.jid.2021.10. 021.

PARK H J， BYUN K A， OH S， et al. The combination of niacinamide, vitamin C, and PDRN mitigates melanogenesis by modulating nicotinamide nucleotide transhydrogenase. Molecules，2022，27(15): 4923. doi: 10.3390/molecules27154923.

BOO Y C. Mechanistic basis and clinical evidence for the applications of nicotinamide (niacinamide) to control skin aging and pigmentation. Antioxidants (Basel)，2021，10(8): 1315. doi: 10.3390/antiox10081315.

YANG X， TANG Y， WANG M， et al. Co-delivery of methotrexate and nicotinamide by cerosomes for topical psoriasis treatment with enhanced efficacy. Int J Pharm，2021，605: 120826. doi: 10.1016/j.ijpharm.2021. 120826.

El-KHALAWANY M， NOUH A H， KADAH A S， et al. Evaluation of safety and efficacy of topical 4% nicotinamide in treatment of psoriasis; among a representative sample of Egyptians (an analytical observational study). Dermatol Ther，2022，35(9): e15734. doi: 10.1111/dth.15734.

TENG Y， YU Y， LI S， et al. Ultraviolet radiation and basal cell carcinoma: an environmental perspective. Front Public Health，2021，9: 666528. doi: 10.3389/fpubh.2021.666528.

THOMPSON B C， HALLIDAY G M， DAMIAN D L. Nicotinamide enhances repair of arsenic and ultraviolet radiation-induced DNA damage in HaCaT keratinocytes and ex vivo human skin. PLoS One， 2015，10(2): e0117491. doi: 10.1371/journal.pone.0117491.

HOEGLER K M， KHACHEMOUNE A. Is the first-line systemic chemoprevention of nonmelanoma skin cancer nicotinamide or acitretin?Int J Dermatol，2021，60(6): 749–750. doi: 10.1111/ijd.15442.

SALECH F， PONCE D P， PAULA-LIMA A C， et al. Nicotinamide, a poly [ADP-ribose] polymerase 1 (PARP-1) inhibitor, as an adjunctive therapy for the treatment of Alzheimer's disease. Front Aging Neurosci， 2020，12: 255. doi: 10.3389/fnagi.2020.00255.


Refbacks

  • There are currently no refbacks.